← Back to Search

Intraocular Lens

LAL + LDD for Cataracts

N/A
Waitlist Available
Research Sponsored by RxSight, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Between the ages of 40 and 80 inclusive on the day the cataract surgery is performed
Be older than 18 years old
Must not have
History of ocular herpes simplex virus in either eye
Patients with sufficiently dense cataracts that preclude examination of the macula in either eye
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial compares the safety of a special adjustable lens with a standard lens in patients needing lens implants, usually after cataract surgery. The special adjustable lens can be fine-tuned using light after it is placed in the eye to improve vision. These lenses are a relatively new option for cataract surgery that allows for adjustments after surgery using UV light.

Who is the study for?
This trial is for English-speaking adults aged 40-80 who are willing to undergo cataract surgery and can follow the study's procedures. Participants will be randomly assigned to receive either the RxSight Light Adjustable Lens (LAL) or a standard monofocal lens. People with eye conditions like ectasia, dense cataracts that block macula examination, previous eye surgeries (except certain pterygium excisions), macular disease, uveitis, or ocular herpes simplex virus cannot join.
What is being tested?
The study aims to compare the safety outcomes of two types of intraocular lenses: the RxSight Light Adjustable Lens (LAL), which can be adjusted after implantation using a special light delivery device, and a standard monofocal control lens implanted during cataract surgery.
What are the potential side effects?
Potential side effects were not specified in the provided information. However, common risks associated with intraocular lenses include inflammation, infection risk post-surgery, visual disturbances such as glare and halos around lights, and potential need for additional procedures if adjustments are required.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 40 and 80 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had herpes in my eye before.
Select...
My cataracts are dense enough to block a clear view of my macula.
Select...
I am taking medication that could harm my eyesight, like tamoxifen.
Select...
I have had uveitis in one or both of my eyes.
Select...
I have a pre-existing condition affecting the central part of my eye's retina.
Select...
I am on medication that makes my skin more sensitive to sunlight.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Light adjustable lens (LAL) and Light Delivery Device (LDD)Experimental Treatment1 Intervention
Group II: Control IOLActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Light Adjustable lens (LAL) and Light Delivery Device (LDD)
2018
N/A
~200

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Cataract treatment primarily involves the surgical removal of the cloudy natural lens and its replacement with an intraocular lens (IOL). The Light Adjustable Lens (LAL) is a novel type of IOL that allows for post-implantation adjustments using UV light, enabling precise customization of vision correction after surgery. This mechanism is significant for cataract patients as it offers the potential for improved visual outcomes and reduced dependence on glasses, addressing individual visual needs more accurately than traditional IOLs.

Find a Location

Who is running the clinical trial?

RxSight, Inc.Lead Sponsor
5 Previous Clinical Trials
272 Total Patients Enrolled
5 Trials studying Cataract
272 Patients Enrolled for Cataract

Media Library

Light Adjustable lens (LAL) (Intraocular Lens) Clinical Trial Eligibility Overview. Trial Name: NCT05202808 — N/A
Cataract Research Study Groups: Light adjustable lens (LAL) and Light Delivery Device (LDD), Control IOL
Cataract Clinical Trial 2023: Light Adjustable lens (LAL) Highlights & Side Effects. Trial Name: NCT05202808 — N/A
Light Adjustable lens (LAL) (Intraocular Lens) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05202808 — N/A
~125 spots leftby Dec 2025